vs

Side-by-side financial comparison of GREENE COUNTY BANCORP INC (GCBC) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

GREENE COUNTY BANCORP INC is the larger business by last-quarter revenue ($22.2M vs $12.5M, roughly 1.8× Avidity Biosciences, Inc.). GREENE COUNTY BANCORP INC runs the higher net margin — 46.3% vs -1398.3%, a 1444.7% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 23.8%). GREENE COUNTY BANCORP INC produced more free cash flow last quarter ($6.2M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 18.9%).

Bank of Greene County is an American federally-chartered savings bank headquartered in Catskill, NY. The bank's branches are located in the Upstate New York counties of Greene, Columbia, Albany, Ulster, and Rensselaer.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

GCBC vs RNA — Head-to-Head

Bigger by revenue
GCBC
GCBC
1.8× larger
GCBC
$22.2M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+410.2% gap
RNA
434.0%
23.8%
GCBC
Higher net margin
GCBC
GCBC
1444.7% more per $
GCBC
46.3%
-1398.3%
RNA
More free cash flow
GCBC
GCBC
$163.1M more FCF
GCBC
$6.2M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
18.9%
GCBC

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
GCBC
GCBC
RNA
RNA
Revenue
$22.2M
$12.5M
Net Profit
$10.3M
$-174.4M
Gross Margin
Operating Margin
52.0%
-1513.5%
Net Margin
46.3%
-1398.3%
Revenue YoY
23.8%
434.0%
Net Profit YoY
37.4%
-117.0%
EPS (diluted)
$0.60
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GCBC
GCBC
RNA
RNA
Q4 25
$22.2M
Q3 25
$21.5M
$12.5M
Q2 25
$20.5M
$3.8M
Q1 25
$20.1M
$1.6M
Q4 24
$17.9M
$3.0M
Q3 24
$16.9M
$2.3M
Q2 24
$16.6M
$2.0M
Q1 24
$15.7M
$3.5M
Net Profit
GCBC
GCBC
RNA
RNA
Q4 25
$10.3M
Q3 25
$8.9M
$-174.4M
Q2 25
$9.3M
$-157.3M
Q1 25
$8.1M
$-115.8M
Q4 24
$7.5M
$-102.3M
Q3 24
$6.3M
$-80.4M
Q2 24
$6.7M
$-70.8M
Q1 24
$5.9M
$-68.9M
Operating Margin
GCBC
GCBC
RNA
RNA
Q4 25
52.0%
Q3 25
47.4%
-1513.5%
Q2 25
53.5%
-4448.7%
Q1 25
44.6%
-8360.9%
Q4 24
45.0%
-4069.6%
Q3 24
39.6%
-4200.9%
Q2 24
41.2%
-4040.4%
Q1 24
39.4%
-2178.6%
Net Margin
GCBC
GCBC
RNA
RNA
Q4 25
46.3%
Q3 25
41.2%
-1398.3%
Q2 25
45.6%
-4089.3%
Q1 25
40.1%
-7360.0%
Q4 24
41.7%
-3439.5%
Q3 24
37.1%
-3441.7%
Q2 24
40.6%
-3461.8%
Q1 24
37.3%
-1943.4%
EPS (diluted)
GCBC
GCBC
RNA
RNA
Q4 25
$0.60
Q3 25
$0.52
$-1.27
Q2 25
$0.55
$-1.21
Q1 25
$0.47
$-0.90
Q4 24
$0.44
$-0.80
Q3 24
$0.37
$-0.65
Q2 24
$0.39
$-0.65
Q1 24
$0.34
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GCBC
GCBC
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$258.3M
$1.9B
Total Assets
$3.1B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GCBC
GCBC
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$155.5M
$254.2M
Q4 24
$166.4M
$219.9M
Q3 24
$370.2M
Q2 24
$190.4M
$575.8M
Q1 24
$471.4M
Stockholders' Equity
GCBC
GCBC
RNA
RNA
Q4 25
$258.3M
Q3 25
$248.2M
$1.9B
Q2 25
$238.8M
$1.2B
Q1 25
$229.0M
$1.3B
Q4 24
$218.4M
$1.4B
Q3 24
$216.3M
$1.5B
Q2 24
$206.0M
$1.2B
Q1 24
$199.2M
$830.9M
Total Assets
GCBC
GCBC
RNA
RNA
Q4 25
$3.1B
Q3 25
$3.1B
$2.1B
Q2 25
$3.0B
$1.4B
Q1 25
$3.0B
$1.5B
Q4 24
$3.0B
$1.6B
Q3 24
$2.9B
$1.6B
Q2 24
$2.8B
$1.3B
Q1 24
$2.9B
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GCBC
GCBC
RNA
RNA
Operating Cash FlowLast quarter
$6.4M
$-156.2M
Free Cash FlowOCF − Capex
$6.2M
$-156.9M
FCF MarginFCF / Revenue
28.0%
-1257.6%
Capex IntensityCapex / Revenue
0.9%
5.7%
Cash ConversionOCF / Net Profit
0.62×
TTM Free Cash FlowTrailing 4 quarters
$47.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GCBC
GCBC
RNA
RNA
Q4 25
$6.4M
Q3 25
$7.0M
$-156.2M
Q2 25
$28.0M
$-199.7M
Q1 25
$7.3M
$-124.8M
Q4 24
$5.3M
$-99.9M
Q3 24
$2.1M
$-65.6M
Q2 24
$24.9M
$-65.0M
Q1 24
$5.6M
$-70.4M
Free Cash Flow
GCBC
GCBC
RNA
RNA
Q4 25
$6.2M
Q3 25
$6.5M
$-156.9M
Q2 25
$27.3M
$-203.0M
Q1 25
$7.3M
$-128.6M
Q4 24
$5.1M
$-103.8M
Q3 24
$2.0M
$-67.3M
Q2 24
$23.4M
$-65.5M
Q1 24
$4.9M
$-71.3M
FCF Margin
GCBC
GCBC
RNA
RNA
Q4 25
28.0%
Q3 25
30.4%
-1257.6%
Q2 25
133.3%
-5277.1%
Q1 25
36.1%
-8174.3%
Q4 24
28.6%
-3491.0%
Q3 24
11.8%
-2881.8%
Q2 24
141.2%
-3204.6%
Q1 24
31.3%
-2012.3%
Capex Intensity
GCBC
GCBC
RNA
RNA
Q4 25
0.9%
Q3 25
1.9%
5.7%
Q2 25
3.4%
86.9%
Q1 25
0.3%
238.6%
Q4 24
1.0%
131.7%
Q3 24
0.9%
72.9%
Q2 24
9.1%
26.0%
Q1 24
4.2%
25.8%
Cash Conversion
GCBC
GCBC
RNA
RNA
Q4 25
0.62×
Q3 25
0.78×
Q2 25
3.00×
Q1 25
0.91×
Q4 24
0.71×
Q3 24
0.34×
Q2 24
3.70×
Q1 24
0.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons